Further, as both GLP-1 receptor agonists and SGLT-2 inhibitors reduce visceral fat, and GLP-1 receptor agonists reduce fat deposits in the liver in patients with NAFLD/NASH (52, 53), this drug combination may be instrumental in the treatment of NAFLD/NASH. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.